Scientiam Pharma has disclosed new 6-aminophenanthridine derivatives acting as Epstein-Barr nuclear antigen 1 (EBNA-1) inhibitors reported to be useful for the treatment of Epstein-Barr virus (EBV)-associated disorders such as post-transplant lymphoproliferative disorder, multiple sclerosis and infectious mononucleosis.

Haisco Pharmaceutical Group Co. Ltd. has identified new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding ligand coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting agent through a linker acting as SMARCA2 degradation inducers and thus reported to be useful for the treatment of lung cancer.

An Anavo Therapeutics BV patent describes new thiophene and thiazole derivatives acting as protein phosphatase 1D (PP-2Cdelta; WIP1) inhibitors.

Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders.

Work at Rubedo Life Sciences Inc. has led to the development of Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors acting as senolytic agents and reported to be useful for the treatment of autoimmune disease, cancer, cardiovascular disorders, cognitive disorders, diabetes, inflammatory, metabolic and neurological disorders, among others.

Nura Bio Inc. has patented new bicyclic heteroaryl compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists.

Work at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have prepared new serine protease NS3/non-structural protein 2B (NS3/NS2B) (dengue virus) and/or (West Nile virus) and/or (Zika virus) and/or Japanese encephalitis virus inhibitors.

Impact Therapeutics Inc. has disclosed new heteroaromatic and heterobicyclic compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Heterocyclic compounds acting as potassium channel subfamily T member 1 (KCNT1) and KCNT1 mutant inhibitors have been reported in a Actio Biosciences Inc. patent as potentially useful for the treatment of neurological disorders.